Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8382893 | 0.83 | ALDH1A1 (0.30) | ALDH1A1ALOX15TSHR | |
| SCHEMBL22632213 | 0.83 | CDK2 (0.41) | ALDH1A1ALOX15TSHR | |
| SCHEMBL31124846 | 0.80 | CDK2 (0.43) | — | |
| SCHEMBL12602353 | 0.78 | PDK2 (0.31) | — | |
| SCHEMBL13322768 | 0.72 | KMT2A (0.35) | — | |
| SCHEMBL21158500 | 0.69 | CDK2 (0.53) | — | |
| SCHEMBL3943483 | 0.69 | HSP90AA1 (0.32) | — | |
| SCHEMBL12636376 | 0.69 | PDE4A (0.34) | — | |
| SCHEMBL16063493 | 0.65 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL16476670 | 0.64 | ALDH1A1 (0.41) | ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11110091-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-11052091-B2 | BRK inhibitory compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-07-06 | — | — | US | disclosed |
| US-20190321366-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10172860-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180085370-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170065592-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| WO-2011157397-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085370-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | ALDH1A1 3435/4885ALOX15 1067/4885TSHR 1315/4885 |
| US-10172860-B2 | Modulators of toll-like receptors | TLR3, TLR2, TLR6 | ALDH1A1 3435/4885ALOX15 1067/4885TSHR 1315/4885 |
| US-11110091-B2 | Modulators of toll-like receptors | TLR3, TLR2, TLR6 | ALDH1A1 3435/4885ALOX15 1067/4885TSHR 1315/4885 |
| US-11052091-B2 | BRK inhibitory compound | BRI3BP, BRSK2, SBK3 | ALDH1A1 3137/4885ALOX15 2601/4885TSHR 4330/4885 |
| US-20190321366-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | ALDH1A1 3435/4885ALOX15 1067/4885TSHR 1315/4885 |
| US-20170065592-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | ALDH1A1 3435/4885ALOX15 1067/4885TSHR 1315/4885 |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | ALDH1A1 2406/4885ALOX15 2030/4885TSHR 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.